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ABSTRACT 
Background 
Bardet-Biedl Syndrome (BBS) and Laurence-Moon Syndrome (LMS) are 
differentiated by the presence of spasticity and the absence of polydactyly in 
LMS. The aims of this study were to determine whether BBS and LMS are the 
same disorder, describe the clinical and genetic epidemiology and examine 
genotype-phenotype relationships. 
Methods 
A population-based, prospective study was conducted. 46 patients from 26 
families were enrolled. Patients and relatives were genotyped at BBS loci. 
Longitudinal and cross-sectional clinical data were analysed. 
Results 
There were at least six BBS genes in the cohort. Characteristic craniofacial 
dysmorphic features were identified. Neurological manifestations were 
prevalent. 2/46 patients were diagnosed clinically as LMS but both had 
mutations in a BBS gene. Major clinical outcomes were similar for all 
genotypes. 
Conclusions 
LMS ~md BBS are the :>arne disorder. It is associated with a characteristic 
cranio-facial dysmorphology and abnormalities in almost every organ system. 
The \\idcspread systemic imolvement and lack of a genotype-phenotype 
con·elation implies that the BBS genes are involved in the same early 
de\ elopmental path\\ay. 
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1 I~TRODUCTION 
1.1 Laurence-Moon Syndrome (LMS) Versus Bardet-Biedl 
Syndrome (BBS) 
In 1866. Laurence and Moon described a family with retinal dystrophy, obesity, 
mental retardation, male hypogenitalism, and a "slouching gait" (Laurence and 
Moon, 1866). More than 30 years later, Bardet and Biedl reported similar 
phenotypes in individuals who also had polydactyly (Bardet, 1920; Biedl1922). 
The cases described by Laurence, Moon, Bardet and Biedl were regarded as the 
same syndrome until the 1980s. Different combinations of the original authors' 
names were used to refer to the disorder: Laurence-Moon-Bardet-Biedl 
syndrome (Abdel-Aziz, 1972; Blume! and Kniker, 1959; Klein and Ammann, 
1969: :VIcLoughlin and Shanklin, 1967), Laurence-Moon-Biedl syndrome 
(Bauman and Hogan, 1973; Bum, 1950; Ciccarelli and Vesell, 1961; Cockayne 
et al, 1935: Krill et al, 1961; McCullagh EP and Leiser AE, 1957; Roth 1947), 
Laurence-Biedl Syndrome (Solis-Cohen and Weiss, 1925) and Laurence-Moon 
Syndrome (Bell. 1958: Dekaban eta!, 1972). 
In 198 !. a new classification for the cases described by Laurence, Moon, Bardet 
and Biedl was proposed, dividing these into two separate syndromes, LMS and 
BBS (Schachat and Maumenee, 1981). The authors proposed that four of the 
five cardinal features, tapetoretinal degeneration, mental retardation, obesity, 
polydactyly and hypogenitalism. should be present for a diagnosis of BBS. They 
differentiated L\1S from BBS by the presence of spastic paraplegia, and the 
absence of obesity and polydactyly in LMS. They cited 21 cases of LMS from 
the literature, though most of these had obesity, three had polydactyly, and only 
a third (7/21) had spastic paraplegia, whereas almost all had ataxia. 
The ne\\' classification of LMS and BBS was adopted, and LMS (OML\1 
245800) and BBS (OMIM 209900) have been regarded as separate disorders 
since the 1980s, differentiated by the presence of spasticity and the absence of 
polydactyly in LMS (Lancet 1988: OMIM; Schachat and Maumenee, 1982). 
BBS is the more commonly reported of the two syndromes, with a prevalence of 
1 in 125.000 to 160,000 in Europe, (Beales eta!, 1997; Klein and Amman, 
1969) and 1 in 65,000 in an Arab population (Farag and Teebi, 1988). The 
cardinal features are retinal dystrophy, obesity, dystrophic extremities, renal 
structural abnormalities and male hypogenitalism (Green eta!, 1989). Other 
features\\ hich arc more variable include renal failure. learning difficulties. 
diabetes and hypertension (Beales eta!, 1999; Green eta!, 1989). The diagnosis 
may be delayed because of the age-related penetrance of many of the clinical 
manifestations (Beales et al, 1999). There is considerable inter- and intra-
familial variation in the phenotype. (Beales et al, 1997; Riise et al, 1997). 
More recently, some authors have suggested that LMS and BBS may represent 
allelic forms of the same condition (Beales et al, 1999). While several disease 
genes have been identified for BBS, the molecular basis of LMS is not known. 
1.2 Molecular Genetics of BBS 
BBS is genetically heterogeneous, with at least eight loci. Five genes have been 
identified: BBSl (llql3) (Mykytyn et al, 2002), BBS2 (16q21) (Nishimura et 
al, 2001). BBS4 (15q22) (Mykytyn et al, 2001), BBS6 (20pl2) (Katsanis et al, 
2000: Slavotinek et al, 2000) and BBS7 (4q27) (Badano et al, 2003a) and an 
additional two loci, BBS3 (3p12) (Sheffield et al, 1994; Young eta!, 1998) and 
BBS5 (2qJ 1) (Young et al, 1999a) have been mapped. In most populations, 
BBS 1 is the most prevalent genotype, accounting for approximately 30-40% of 
patients (Beales et al, 2001). A common missense mutation, M390R, in BBSl 
accounts for up to 80% of all BBS 1 mutations (Beales et al, 2003; Mykytyn et 
a!. 2003 l. 
Despite the identification of five BBS genes, the molecular mechanism 
responsible for the syndrome remains obscure. The BBS6 gene (MKKS) 
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encodes a type 2 chaperonin that is probably involved in protein folding (Stone 
et aL 2000). The BBS4 gene product shares sequence similarity with 0-
GlcNAc-transferase (OGT) (Mykytyn et al, 2001) but whether it is 
enzymatically active is uncertain. The BBSl, BBS2, and BBS7 proteins share 
structural features (Badano eta!, 2003) but no functions have been assigned to 
them. 
The inheritance of BBS has traditionally been considered as autosomal recessive 
(Mykytyn et al, 2003). However, following the cloning of BBS genes, sequence 
analysis has shown that in some families, three mutations in two BBS genes are 
necessary for pathogenesis (Badano eta!, 2003a; Badano et al, 2003b; Beales et 
a!, 2003; Katsanis et al, 200la; Katsanis eta!, 200lb; Katsanis eta!, 2002). The 
discovery of triallelic inheritance in BBS has generated the hypothesis that BBS 
may, at least in some cases, follow oligogenic inheritance, in which specific 
alleles at more than one locus cause <.meLlor modify the severity of the phenotype 
(Badano and Katsanis, 2002). 
Further understanding of the relationship between genotype and phenotype may 
help to clarify how the different BBS genes and their products interact. 
1.3 Clinical ~Ianifestations of BBS: Critique of the Literature 
1.3.1 Visual Loss 
The studies involving larger cohorts of BBS patients will be reviewed. 
Riise et a! reported the ocular findings in 44 Scandinavian BBS patients, with a 
maximal follow-up time of 9 years (Riise, 1987). Patients were ascertained 
through the Swedish and Danish Retinitis Pigmentosa registers, the Swedish 
register of the visually impaired child and the Norwegian Laurence-Moon-
Bardet-Biedl Association. The criteria for inclusion were retinal dystrophy (a 
mandatory finding) plus at least two of the traditional cardinal signs, which were 
not specified. The ascertainment and inclusion criteria bias this sample towards 
patients with visual impairment, so the conclusions drawn about visual function 
may be pessimistic. One of the strengths of this study is that all patients were 
examined using the same protocol, which is clearly described, in the same centre 
during a one day period, which should help to minimise inter-observer bias. The 
first reported visual symptom was night blindness, at an average age of 4 years 
(range 0 to 16 years). The mean age for first visual problems during the day was 
6.4 years, however this is likely to be influenced by investigation bias since 
routine testing of acuity in schoolchildren takes place at 7 years, causing the 
peak of first daytime visual impairment at this age, which the authors show. 
There is a deterioration in visual acuity and fields with age for all patients, 
maximal from 10 to 20 years of age with a wide variation in rate. 
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A subsequent study on the intrafamilial variation in BBS reported the wider 
phenotype in a subgroup of these patients, for 25 patients from 11 families, all of 
whom had at least one sibling with BBS (Riise eta!, 1997). There was 
substantial inter- and intrafamilial variation, with a variation of up to 14 years 
for the age at first sign of daytime visual impairment between siblings. 
109 BBS patients identified through the Laurence-Moon-Bardet-Biedl Society 
(UK) and the Guy's Hospital (London, UK) genetic clinic BBS register were 
surveyed using a standardised questionnaire (Beales eta!, 1999). This was 
described as a population survey by the authors, though the ascertainment may 
have been biased towards those with more severe problems, who were referred 
to the genetic clinic or sought support from the LMBB Society. However, 
compared with some of the other studies which have recruited patients through 
ophthalmology clinics (Leys et al, 1988; Fulton eta!, 1993; Riise et al, 1996; 
Riise eta!, 1997; Riise et al, 1996; Jacobson et al, 1990), there may have been 
less of a bias towards visual problems. In this relatively large group of 109 BBS 
patients. visual impairment occurred in 98% before 20 years of age. 93% of 
patients had signs of rod-cone retinal dystrophy diagnosed by an 
ophthalmologist. the remaining 7 patients were all less than 8 years of age. 
6 
Several reports on different aspects of clinical features in Newfoundland BBS 
patients have been produced. One of the strengths of this study is the attempt 
made at complete ascertainment by using different routes to identify patients, 
including a Genetics Ophthalmology clinic, Canadian National Institute for the 
Blind (CNIB) registry, family studies and requesting charts of patients with 
diagnoses of BBS or Laurence-Moon-Biedl syndrome from other hospitals. All 
28 patients examined had severe retinal dystrophy, but only two had typical 
retinitis pigmentosa, which was previously thought to be a characteristic finding 
in BBS. Visual acuity declined rapidly with age, all patients except one child of 
12 years were registered blind (Green et al, 1989). 
O'Dea et al subsequently reported longitudinal data for the cohort reported by 
Green et al, and compared the natural history of 38 BBS patients with 58 
unaffected siblings (O'Dea eta!, 1996). The median age at registering blind was 
18 years. and all were legally blind by 30 years of age. 
The findings of these studies are consistent, and show that the visual loss in BBS 
is severe and early onset. Visual function declines with age, particularly during 
the second decade of life, though the rate of decline varies widely. Most patients 
are legally blind by 30 years of age. 
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1.3.2 Renal Function 
There are very few studies which have used a standardised protocol and 
comprehensive testing to investigate renal structure and function in BBS. Most 
of the studies had the aim either of describing the phenotype of BBS, or the 
visual function, and for several of these studies (Beales eta!, 1999; Leys eta!, 
1988: Riise eta!, 1997: Farad and Teebi, 1988) the renal data was reported 
without specifying how many patients were investigated, so the prevalence of 
renal abnormalities may be underestimates. 
One study. conducted in Newfoundland, undertook to describe specifically the 
renal features of BBS (Hamett eta!, 1988). The 20 patients in this study were 
investigated more thoroughly than in other studies, following a defined protocol. 
Clinical end-points such as hypertension were defined. All patients had some 
abnormality in renal structure, function or both. Fifty percent (10/20) of patients 
had hypertension and 15% (3/20) had chronic renal failure. Urine concentrating 
ability and acidification were compared to controls. There was a significant 
difference in urine concentrating ability between cases and controls. Nineteen 
patients had a renal ultrasound scan and intravenous pyelogram; 95% (18/19) 
patients had calyceal clubbing or blunting, which were unrelated to 
demonstrable vesico-ureteric retlux, and (17/19) had persistent fetal lobulation. 
These data lead to the conclusion that renal abnormalities are a cardinal 
manifestation of BBS (Green eta!. 1989). 
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The strengths of this study include the method of ascertainment which should 
not have a major bias in terms of renal abnormalities, and the use of a thorough 
protocol which was performed in the same centre. 
Longitudinal data from the Newfoundland cohort was subsequently reported for 
38 patients. with a mean age of 35 years and a follow-up of 7 years (O'Dea et al, 
1996). Clinical endpoints such as chronic renal failure (CRF) and hypertension 
were defined. and a standardised protocol was used. Hypertension was present 
in 66% (25/38) patients with a median age of onset of 34 years, compared with 
11% of siblings (who did not have BBS). CRF occurred in 25% (9/36), and by 
48 years, 25% of patients had CRF. Twenty-nine patients had a renal ultrasound 
scan. Fetal lobulation was present in 96% of patients, and abnormal calyces in 
96%. 
The major weaknesses of other studies reporting the prevalence of renal 
abnormalities is the paucity of renal investigations and lack of definitions. In a 
survey of 109 patients with BBS, only 52% (571109) had renal imaging, by 
ultrasound scan in 35%, isotope renography in 40% and intravenous 
pyelography (IVP) in 14% (Beales et al, 1999). Five percent (61109) of patients 
were reported as having chronic renal failure (defined by raised plasma urea and 
creatinine), but it was not clear how many were investigated. Calyceal clubbing 
or blunting was reported in only 10% (6/57) and fetal lobulation in 12% (7/57), 
ho\\ e'er these would be difficult to detect using isotope renography, and there 
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would be inter-observer inconsistencies due to several different radiologists 
interpreting the imaging studies. Both these factors would likely lead to under-
reporting of renal structural anomalies. 
Similarly, no investigations of renal function were performed in a study of 44 
Scandinavian BBS patients (Riise et al, 1997). Information about renal disease 
was obtained from a questionnaire and review of medical records. Sixteen 
percent (4/25) had either a congenital renal anomaly, which was not specified, or 
reduced function of the kidneys (on the basis of raised serum creatinine). 
Because investigation for renal anomalies was not part of the protocol, this 
likely resulted in underestimates. 
1.3.3 Mental Retardation 
Mental retardation was regarded as a cardinal feature of LMS and BBS since the 
earliest reports, based on observations rather than formal psychological testing 
(Laurence and Moon, 1866; Klein and Amman, 1969; Schachat and Maumenee, 
1982). However, when formal intelligence testing was undertaken using tests 
appropriate for the visually impaired, the majority of patients were found to 
have an IQ in the low-normal range. In the Newfoundland cohort, only 13/32 
( 41%) of patients were mentally retarded (IQ<70) (Green et a!, 1989). 
In a survey of 109 BBS patients, the prevalence of learning difficulties was 
62%. ho\\ever the term was not defined (Beales et al, 1999). It was stated that 
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the learning difficulties were mostly mild to moderate, but it is not clear whether 
they result from difficulties due to impaired vision or intellectual function, nor is 
it clear how these patients were tested since only a minority were seen by the 
author, the rest of the data being ascertained from questionnaires. Ascertainment 
through a BBSILMS support group may have caused a bias, since parents of 
children with leaming difficulties may be more likely to join a support group. 
Hence the prevalence for behaviour problems and learning difficulties of 33% 
and 62 % respectively in BBS from this survey may be an over-estimate. 
Twenty patients with BBS from Arab families who were refened to the Kuwait 
genetic clinic for diagnosis and/or counselling were all reported to have had 
mental retardation with an IQ between 25 and 65, but the protocol and testing 
used in this study were not given (Farad and Teebi, 1988). In contrast, the 
majority of 44 Scandinavian BBS patients studied were described as having 
normal intelligence, though none were tested formally (Riise et al, 1996). 
1.3.4 Diabetes Mellitus 
In most studies of BBS patients, the number investigated for the presence of 
diabetes mellitus (DM) was not specified. A prevalence of 6% for DM in a 
sun·ey of 109 BBS patients, and 12% in 25 BBS patients was reported, (Beales 
eta!, 1999: Riise eta!, 1997), however these are likely to be underestimates, 
since subclinical diabetes mellitus would not be detected without investigation. 
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In the Newfoundland study, earlier protocols involved glucose tolerance testing 
for the majority of patients (Green et al, 1989; O'Dea et al, 1996). Lifetable 
analysis showed that 50% of patients were diabetic by 50 years, though this was 
based on limited longitudinal data. The data suggested that diabetes mellitus is a 
feature in at least a third of BBS patients during the clinical course of the 
disease, but longer follow-up would give a more accurate figure. 
1.3.5 Obesity 
Varying definitions of obesity used in different studies of BBS patients may 
account for the difference in prevalences. The prevalence of obesity in a cohort 
of 109 BBS patients was reported as 72%, using a definition of Body Mass 
Index (BMI) greater than 29 kg/m2 (Beales et al, 1999), whereas the current and 
previous studies of the Newfoundland BBS patients used a definition of BMI 
greater than 27 kg/m2 (O'Dea et al, 1996), giving a higher prevalence. However, 
all studies show that a majority of patients with BBS develop obesity, using any 
of the definitions. These studies include children from the age of 1 year, so it 
appears that obesity may develop in early childhood, although there are no 
longitudinal data on this. 
1.3.6 Life Expectancy 
8/38 (21 '7r) of the Newfoundland BBS patients had died by the end of the 
previous assessment. at ages ranging from 1 to 63 years (O'Dea eta!, 1996). 
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Renal failure was present in 75% at the time of death, and was the primary cause 
of death in 38% (3/8). Survival analysis showed that 25% of BBS patients were 
dead by 44 years of age, which was significantly younger than their unaffected 
siblings. The data were too scanty to draw a conclusion, but suggested an 
adverse prognosis for life expectancy in BBS. 
A review of 14 death certificates of BBS patients revealed that renal disease was 
a factor in 50% (7 /14) (Riise, 1996). The mean age of death was 46.4 years for 
the 7 women, and 43 years for the 7 men. The number of patients was small, 
ascertainment was incomplete and the data were obtained from a retrospective 
rather than prospective cohort, so the ages of death seen in this study should not 
be regarded as accurate predictions for the life expectancy of other groups of 
BBS patients. Despite these flaws, the data suggest that BBS is associated with 
an adverse prognosis for life-expectancy, and that renal disease contributes to 
the death of some patients. 
1.4 Genotype-Phenotype Studies in BBS 
No population-based study with large numbers of patients defined by genotype 
has been reported previously. Studies which have compared the BBS phenotype 
with genotype have noted only minor phenotypic differences (Beales et al, 1997; 
Carmi et al, 1995; Riise et al, 2002). 
13 
The clinical features\\ ere compared between 12 Bedouin BBS3 patients, seven 
BBS-+ patients and nine BBS2 patients (Carmi et al. 1995). They concluded that 
BBS~ is associated with 4 limb polydactyly, BBS4 with early onset morbid 
obesity and BBS2 \Vith a lesser degree of obesity. However, the number of 
patients \vas small, and the suggested BBS3 phenotype was not confirmed in a 
Newfoundland BBS3 family (Young et al, 1998). Four of the five patients in the 
Newfoundland BBS3 family had polydactyly restricted to their feet, and the 
obesity in these patients was reversible with appropriate lifestyle changes. 
No clinical differences were found between 29 European BBS families linked to 
BBS l. BBS2 or BBS-1-. or unlinked (Bruford et al. 1997). In another study of 18 
BBS families ( 14 European and 4 Middle-Eastern). minor phenotypic 
differences \\ere obsen·ed between families linked to eli fferent loci (Beales et al. 
1997). BBS 1 affected offspring were taller than their parents, whereas BBS2 
and B BS-1- patients were significantly shorter than their parents. The authors 
concluded that the different BBS genes may affect growth characteristics such 
as height. The number of patients was small. with the BBS4 group comprising 
only one !amily of 2 affected individuals. 
In a more reL·ent report. the clinical features of 3 ~orwegian BBS4 sibling pairs 
\\Cre descnbed (Riisc ct al. 200.2). The phenotype shO\\ed inter- and intra-
t.amiii~tl \ ~tri,thliiity. ~md there\\ ere no major differences in clinical features 
I-I 
from other BBS patients, though the authors suggested there may be a 
charactenstic ocular fundal appearance in BBS4 patients. 
1.5 Advantages of ~ewfoundland for the Study of BBS and LMS 
Newfoundland has a relatively isolated population, 90% of whom are descended 
from migrants from south-west England and Ireland (:viannion. 1986). Genetic 
founders have given rise to clusters of hereditary disorders (Parfrey et al, :200:2). 
Persistent isolation. large sibships. and a high coefficient of kinship have 
facilitated the study of rare autosomal recessive disorders such as BBS, which is 
more common than in other populations (Bear eta!, 1987; Bear et al, 1988; 
Green et aL 1989: Harnett et al, 1988; O'Dea et al, 1996). Furthermore, the 
health care structure. with a single tertiary refeiTal centre, facilitates 
ascertainment for population-based studies. 
1.6 Objectives of Study 
This study extends the analysis of the clinical course of the Newfoundland BBS 
and L\1S patients. and for the first time compares the clinical and molecular 
data for this cohort. Comprehensive ascertainment has enabled all cases of BBS 
and L\1S to be identified in the Kewfoundland population. Longitudinal clinical 
data from more than :20 years of follO\\ -up has been obtained. 
l:' 
The objecti \ es of the current study were: 
1. To determine whether LMS and BBS are the same disorder. 
To describe the clinical and genetic epidemiology ofBBS and LMS. 
3. To determine whether there are genotype-phenotype relationships in BBS. 
4. To describe the clinical course of BBS/LMS. 
5. To extend the phenotype by examining in more detail other organ systems, in 
particular respiratory, gastro-intestinal, neurologic systems and craniofacial 
dysmorphology. 
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2 METHODOLOGY 
2.1 Ascertainment 
Patients were initially ascertained in 1979 through an Ocular Genetics Clinic 
and the registry of the Canadian National Institute for the Blind (Green eta!, 
1989). All patients with retinal dystrophy and any clinical feature compatible 
with BBS or L:viS were enrolled in this prospecti\e study. Subsequent 
ascertainment was through family studies. a search of diagnostic codes for BBS 
and LMS in provincial hospitals and the Provincial Genetics Program. Two 
patients of ~ewfoundland parentage living in Ontario referTed themselves. 
Informed consent was obtained, and the study was approved by the Human 
Investigation Ethics Committee of :Yfemorial University of Newfoundland. 
2.2 Patients 
The cuncnt study cohort consisted of 46 patients from :26 families. Twenty-six 
were male and 20 female, with age range of 1.5 to 67.9 years (median 44 years). 
All patients had at least 4 cardinal features (retinal dystrophy, obesity, renal 
structural abnormalities. male hypogenitalism. dystrophic extremities) or three 
cardinal re~ttures if there \\as an affected sibling. Consanguinity was 
documented in 27'1i 1 7/26) families. and suspected in another 15% (4/26) on the 
bas1s of shared sum~1mes on both sides of the family. 
2.3 Data Collection 
Formal. protocol-dri\'en assessments were undertaken in 1986 (Green eta!, 
1989: Hamett et al. 1988), 1993 (O'Dea et al, 1996) and 2001. These included 
tests of height and weight, blood pressure, visual function, intelligence, glucose 
tolemnce. pituitary function, renal function and imaging, and measures of head, 
extremities. and genitalia. 
In the cunent study, medical charts were reviewed for all46 patients; 10 patients 
were deceased by 2001. Medical data was also obtained from interviews with 
pat1ents. caregivers and family doctors. Twenty-six patients had a clinical 
examination. performed by the same clinician (SJM), which included an 
examination of the neurological system and dysmorphic features, 
anthropometric measurements of the head, face, hands, feet and genitalia, and a 
systemic examination. including height, weight and blood pressure. Twelve 
patients were also examined by another clinical geneticist. Quantitative 
dysmorphic features were compared with normal values using standardised 
charts (Hallet a!, 1995). Slide photographs for 19/26 patients were reviewed by 
two other clinical geneticists to score qualitative facial dysmorphic features. 
Neurological signs were reviewed in seven patients by one neurologist. 
:\inetcen patients had a speech assessment using a standard protocol that was 
administered by two speech pathologists. This included diadochokinetic tests 
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which measure the ability to make rapid alternating speech movements, as a 
measure of oro-motor co-ordination. The times to repeat syllables ("puh", ·'tuh'', 
"kuh" twenty times. and "puhtuhkuh" ten times) were recorded and compared 
with normal values (Shipley and McAfee, 1998). 
Blood samples were taken for measurement of urea, creatinine, liver enzymes. 
random glucose and glycosylated hemoglobin. DNA was extracted from venous 
lymphocyTes for 817c: (21126) families for genotyping, haplotype and linkage 
analysis. and mutation screening (Davidson eta!. 2003: Katsanis et al, 2000; 
Woods et al. 1999: Young et a!. 1998; Young et a!. 1999a; Young et a!. 1999b ). 
Urine samples were obtained for urinalysis, microscopic analysis and culture. 
Psychiatric diagnoses using DSM-IV criteria were confirmed by a psychiatrist, 
on the basis of medical chart review. Fourteen patients had a renal ultrasound 
scan in 2001, and a further 18 patients had renal ultrasound scans in previous 
ass~ssmcnts. In seventy-eight percent (25/32) of cases, the renal ultrasound scan 
was reported by the same radiologist. 
Tests of \erhal intelligent quotient (VIQ) were performed for 23 adults and 1 
child using the Wechsler Adult Intelligence Scale (WAIS) and Wechsler 
lntciiigellCC Sc~tlc for Children (WJSC-III) respectively. Twenty-two of these 
were reported prc\iously (Green et al. 1989). Fourteen patients also had a 
pcrform~tncc IQ ( PIQ 1 test. The Haptic Intelligence Scale (ShuiTager and 
[l) 
Shunager). which is designed for those with severe visual impairment, was used 
for 13. and one child with adequate vision was tested using the WISC-IIL 
Twel\ e of these patients were reported previously (Green et al, 1989). 
2.4 Detinitions 
The follo\\ ing definitions were used: 
Barder-Biedl Syndrome: presence of at least four cardinal features (retinal 
dystrophy, obesity, renal abnormalities, male hypogenitalism, dystrophic 
extremities) or presence of three cardinal manifestations in a sibling of an 
affected person with four cardinal features. 
Laurence-Moon Syndrome: presence of retinal dystrophy, obesity, spasticity, 
and at least one of the following features (hypogenitalism or mental retardation) 
in the absence of polydactyly. 
Regisracd Blind: visual acuity< 20/200 or visual field< 20 degrees in the better 
eye. 
Obesity: Body :viass Index, BMI > 27 kg/m2 
Hypertension: Sitting systolic blood pressure> 150 mm Hg or diastolic blood 
pressure > 90 mm Hg or taking antihypertensive medication. 
Modamc Chronic Renal Failure: Estimated creatinine clearance< 60 mllmin 
using formula of Cockcroft and Gault (Cockroft and Gault, 1976) or serum 
crc~lti nine> !50 micromol/1 in adults, or> 100 micromol/1 in children< 2 years. 
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Mild Chronic Renal Fuilure: Estimated creatinine clearance 60- 90 mllmin, or 
serum creatinine 1:21 - 150 micromol/1. 
Diub!:'tes "'vfellitus: Taking hypoglycemic therapy (diet/oral medication/insulin) 
or fulfilling the diagnostic criteria of the 1998 clinical practice guidelines for the 
management of diabetes in Canada (Meltzer et al, 1998). 
The age of onset of hypertension. diabetes mellitus. or renal failure was 
considered to be the age at\\ hich the clinical end-point\\ as first recorded in the 
medical chart. 
') -
-·:l Data Analysis 
Kapbn-:\leier survival analysis \\as performed for clinical endpoints of 
blindness. diabetes, hypertension. renal failure, cholecystectomy and death. The 
log rank test was used to compare ages of onset for genotypes. Differences 
between continuous variables were evaluated using two-tailed Student's t-test 
for l\\ o groups. and A.'-JOVA with Bonferroni adjustment for multiple 
comp~1risons for more than two groups. A result was regarded as statistically 
significant if the p value was below 0.05. The denominator used in the 
calculation of prevalence for clinical endpoints varied. depending on the number 
of patients a\ailable for testing. 
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3. RESULTS 
3.1 Genetic Epidemiology of BBS in Newfoundland 
Thirty-one percent (461150; 95% confidence interval: 23.6%-38.4%) of the 
siblings in the 26 families were affected. The current prevalence ofBBS in 
:\fewfoundland is approximately 1 in 18,000,. which derives from 28 living 
affected people in 510,000 (population of Newfoundland). Six subjects are now 
living in a different province, and twelve are deceased. 
Blood \vas obtained from 87% (40/46) of patients. 2/40 (1 family) were 
excluded from all known BBS loci, implying they have an as yet unidentified 
BBS locus. and linkage results were inconclusive in 4/40 (3 families) due to 
small family size. In 34 patients in whom the genotype has been identified, 42% 
(15/3-J.) have a mutation in BBS6 and 22% (8/34) in BBSl. All six families 
affected with BBS 1 are homozygous for the same mutation, whereas three 
mutations have been identified in the eight families with BBS6 (Table 1). Five 
affected members of one family showed linkage to BBS3. A complex 
consanguineous family with five affected members was used to locate the BBS5 
locus (Young et al, 1999a). One patient is homozygous for a BBS2 mutation, 
and heterozygous for yet another BBS6 mutation~ All patients from whom DNA 
is availahlc (877r. 40/46) have been tested for all six of the BBS mutations 
obscn cd in the :\'C\\ foundland population but no other cases have been found in 
"hich an affected person has mutations in more than one BBS gene. 
3.2 Diagnosis of Bardet-Biedl Syndrome Versus Laurence-lVIoon-
Syndrome 
Forty-four of 46 patients identified with either BBS or LMS met the diagnostic 
criteria for BBS. Two met the diagnostic criteria for LMS. Both had retinal 
dystrophy, spastic ataxia, hypogenitalism, mild mental retardation and no 
polydactyly. One was from a large consanguinous pedigree which showed 
linkage to BBS5: spasticity\\ as not present in another affected sibling, or two 
affected cousins. The other LMS patient had mutations in the BBS6 gene. Thus, 
although these patients were diagnosed clinically as having LMS. they had 
molecular genetic changes diagnostic of BBS. 
3.3 Major Clinical :VIanifestations 
3.3.1 Blindness 
Ninety-one percent (42/46) of patients were registered blind (Table 2), with a 
median a2:e of 18 years (Fi swre 1 ). Those not registered blind were all children 
.._. "' '-' ._. 
and all had \isual impairment by six years. The age to register blind was similar 
across all genotypes (Table 3 ). 
3.3.2 Dystrophy of Extremities 
Br~tchydact; ly \\ ~~s present in the feet of all patients (36/36), and in the hands in 
S6r i i -~ !/_\() 1. S) nd~tct; ly uC(LJJTed in 9)!;; (35/37 ). mostly 2/3 toe syndactyly. 
Polydactyly \Vas more variable, being present in 63% (29/46) of cases (Table 2). 
Figure .2 ~hO\\ s the distribution of polydactyly by genotype. It was present in all 
genotype groups, except BBS5, and its extent varied widely within a genotype. 
3.3.3 Obesity and Height 
Body \1ass Indices (BMI), were available for 96% (44/46) of the patients. All 
were obese at some time, except a child who died at 18 months (Table 2). The 
mean BMI of all available measurements over time was 35.5 kg/m2, while the 
mean of the maximal BMis was 44 kg/m2. Morbid obesity (BMI greater than 40 
kg/m2) \vas present in 25% (11144) individuals. There was no significant 
clitlerctll'C in BMI with gender or genotype. Maximal BMI measurements with 
the corresponding genotypes are shown in Figure 3. 
The median adult heights (N=36) were 166 em (51h centile) for males, and 157 
em ( l Ot 11 - :25[11 centi le) for females. There was no significant difference between 
genotypes. Eleven percent (4/36) of adult patients had tall stature (height greater 
than (1r cq ual to the 90th centi le ). Five of the six children had tall stature. 
3.3.-t Diabetes Mellitus 
Diabetes mellitus occurred in 48% (22/46) of patients (Table 2) and impaired 
glucose toler~mce was diagnosed in a further four. The median age of onset of 
diabetes mellitus was 43 years (Figure 4) and there was no significant difference 
among genotypes (Table 3). 
3.3.5 Hypertension 
Hypertension was common, with 67% (31146) affected individuals (Table 2). 
The median age of onset was 34 years (Figure 5). Hypertension was associated 
with all genotypes ex.cept BBS2 and there was no significant difference in age of 
onset among genotypes (Table 3). 
3.3.6 Renal Abnormalities 
All 32 patients who had a renal ultrasound scan had an abnormality detected 
(Table 2 ). Fetal lobulation was seen in 84% (26/31). Calyceal blunting, clubbing 
or diverticula was present in 78% (25/32), and cysts in 7Y!o (23132). Forty 
percent ( l3/32) had loss of cortico-medullary differentiation. 
Estimated creatinine clearance was available for 89% (41146) of patients and 
serum creatinine in three others. Moderate chronic renal failure occuned in 20o/c 
(9/44) (Table 2) with a median age at onset of 57.6 years (Figure 6). Four 
patients progressed to end stage renal disease, a further seven had mild chronic 
renal i"ailurc. and ren~tl impairment occurred in all genotypes ex.cept BBS2 (but 
thi:-; p~tticnt \\as only l 6 year:-; old at last foiiO\v-up). 
3.3.7 Genital and Reproductive Abnormalities 
These are shown in Table 4. Male hypogenitalism was present in all but one of 
the males examined. Other abnormalities included undescended testes, 
hypospadias. phimosis, recurrent urethral strictures (requiring surgery) and 
posterior urethral valves. None of the males had offspring. 
In the femule LMBBS patients, gynecological disorders were common, and 
present in all genotypes. liTegular menses occurred in 65% (13/20), 25% (5/20) 
had menorrhagia, 20% (4/20) had a hysterectomy for menorrhagia (two patients) 
or endometriosis (two patients). Two females, both with a BBS 1 genotype, each 
gave birth to one live born, healthy offspring. 
3.4 Neurological, Psychiatric and Speech Abnormalities 
A wide-based, unsteady gait and impaired limb co-ordination were present in 
86% ( 18/21) of the patients. Twenty-one percent (5/24) had spasticity. All four 
I i m bs were affected in four patients and only the lower limbs were affected in 
the other. 
Abnorm~tl f~1ci~tl movements were observed in 75% (15/20) of patients 
representing all genotypes. Lower facial movements were more often affected 
than upper and 307c (6/20) had difficulty smiling. In most individuals the facial 
muse lcs \\ere not weak: rather, the defects in movement appeared to be due to 
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impaired co-ordination or an apraxia. Facial movements were asymmetrical in 
-1-0(/r ( 8/20) of cases. 
The range of eye movement was limited in 81% (17/21) of patients. Upward 
gaze was more often affected than hmizontal or down gaze. Eight individuals 
had severe limitation in all directions. The abnormality was not con-ected by 
oculocephalic manoeuvres, implying that the level of the defect is at or below 
the midbrain. 
Thirty percent (1-1-/46) of patients had a psychiatric disorder. Anxiety and mood 
disorders were the most prevalent, occuning in 20% (9/46) and 9% (4/46) of 
patients respectively. in all genotypes. Two-thirds (6/9) of patients with an 
anxiety disorder presented with somatic symptoms. which were diagnosed as 
psychosomatic following negative investigations. In three cases there were over 
ten such admissions. All except three presented between 20 and 40 years of age, 
two were diagnosed in childhood. Patients with mood disorders presented 
between 2) ~md -J.) years of age and included three with major depression, of 
whom two required treatment as in-patients, and one with bipolar disorder, who 
had numerous hospital admissions. One child with a BBS6 genotype had a 
diagnosis ul· autistic spectrum disorder. and required special education. 
Furm~d intelligence testing re\ealed a mean VIQ of 7) (range 53 to 102, N=24), 
ancl PIQ ui' S~ (r~l!lge -J.-1- to 105. :.J=l-1-l. A minority of patients had an IQ less 
Y'7 
-· 
than 70: 33% (8/24) for VIQ and 21% (3114) for PIQ. The BBS3 patients had a 
significantly higher VIQ than the BBS6 and unknown genotype groups (p=.038 
and p=.015 respectively). There was no significant difference in PIQ among 
genotypes. 
Speech assessment showed that the patients' times for syllable repetition in each 
of four tests were markedly prolonged compared with normal values (p<.0001). 
The mean time for 20 repetitions of "puh", "tuh", "kuh" and 10 repetitions of 
"puhtuhkuh'' were 14.1, 13.1, 12.9 and 14.4 seconds, respectively, compared 
with normal mean values of 3.3, 3.3, 3.7 and 5.7 seconds, respectively. These 
data indicate a significant impairment of oro-motor co-ordination (Figure 7). 
These abnormalities were seen in all genotypes tested (BBS1, 3, 5, 6, and 
unknown). 
3.5 Craniofacial Dysmorphology 
Table 5 shO\\S the prevalence of craniofacial dysmorphic features, which are 
illustrated in Figures 8 and 9. Dysmorphic features were present in all 
genotypes. and there was no clustering of specific features with genotype. 
Ninety-two percent had brachycephaly, and the majority had macrocephaly, 
bitempor~ll nanowing. large ears, high arched palate, short narrow palpebral 
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fissures. and frontal balding (in males). Other common features included ptosis, 
a long shallow philtrum, thin upper lip and small downturned mouth. 
3.6 Medical Problems 
Table 6 shows the medical problems which occurred in at least two BBS 
patients. other than the major manifestations shovm in Table 2. There is no 
evidence of clustering for any of these clinical features with genotype. The more 
common medical problems were present in patients \\ith several different 
genotypes. 
3.6.1 Hepato-biliary Disease 
Cholecystectomy for cholelithiasis was perfmmed in 37'7c (17/46) of patients, in 
55% ( 11120) of females and23'1- (6/26) of males. By 30 ;ears of age, 25% of 
patients had a cholecystectomy (Figure 10). There was a trend towards an earlier 
age to onset for females (p=0.08). 
Liver enzymes were elevated in eight patients, unrelated to episodes of gall 
stone disease. This showed a cholestatic profile (increased alkaline phosphatase) 
in fi\C. hepatitic profile (increased hepatic transaminases) in three, and both 
cholcstattc clllU hcpal!ltc in one. 
3.6.2 Colonic Disorders 
The group \\ilh colonic dysmotility included one child ,,·ith a BBS6 genotype 
who had Hirschsprung Disease. One patient had a history of chronic 
consttpct!tun since ectrl: chilcilwod. Four patients had irntable bowel syndrome 
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with ages at onset bet'vveen 29 and 39 years. Investigations, including barium 
enema. \\ere negative. 
3.6.3 Asthma 
Asthma occurred in 28% (13/46) of cases. All 13 patients with asthma used 
inhalers or nebulisers regularly, and 8113 (62%) required hospital admissions. 
One patient died of cor pulmonale secondary to chronic asthma. 
3.6.4 Congenital Heart Disease 
The cases of congenital heart disease involved one ventricular septal defect and 
one case of aortic valve stenosis. Another patient had complex anomalies, 
including aortic valve stenosis, coarctation of the aorta, left aortic arch and 
abemlllt right subclavian artery. 
3.6.5 Other :Yledical Problems 
ldiop~tthic edema occulTed in 8 patients, two of whom were male, with ages at 
onset bet ween 19 and 51 years (mean 34 years). Upper and lower limbs were 
involved in five patients, and only the lower limbs in three. Three patients 
received diuretic therapy, one improved with antithrombotic stockings. None 
had renal or cardiac impainnent at the time of diagnosis. 
Chronic serous otitis media occurred in 20% (9/46). This caused conductive 
hearing loss in four. and five patients had t-tubes inserted. 
Hyperhidrosis of the hands and feet was self-reported and noted on examination 
in nine cases. It was recorded in the medical chart for two patients, one of whom 
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was deceased at the time of the assessment. In one patient it was sufficiently 
severe to prevent him from reading Braille. 
Epilepsy occurred in five patients, four of whom had childhood onset. Most 
were generalised tonic-clonic seizures. The adult onset disease involved absence 
SeJZUl'CS. 
Of six patients with thyroid disease (two male, four female) three had 
hyperthyroidism. and three hypothyroidism. 
3.7 Death 
The median survival of the cohort was 63 years (see figure 11 for survival 
curve). T\\ehe patients died between the ages of 1.5 and 68 years, with a 
median age of .:.\.6 years. The causes of death were as follows: myocardial 
infarction (3). cerebrovascular disease (1), end stage renal disease (ESRD) (2), 
renal L·arcinoma ( l) and septicemia due to urinary tract infection (1). Two 
patients dice! of post-operative complications, one following surgery for 
Hirschsprung disease. the other after colonic resection for a major lower gastro-
intestinal bleed, of unknown etiology. This patient also had ESRD. The other 
deaths were clue to pulmonary embolus in a patient with morbid obesity, and 
aspiration pneumonia following a seizure due to a meningioma. 
~I 
-L DISCL'SSIOl\ 
4.1 Diagnosis of Bardet-Biedl Syndrome Versus Laurence-Moon 
Syndrome 
The asccrtai n ment of patients throughout the province via several different 
routes means that all cases of BBS and LMS in the Newfoundland population 
should have been identified. The patients were initially identified based on 
retinal dystrophy, a feature that is common to BBS and LMS. They were 
enrolled in the study if they had other features suggestive of BBS or LMS. The 
clinical i'eatures differentiating LMS from BBS are the presence of a spastic, 
ataxic gait and the absence of polydactyly in LMS. Two patients met the 
diagnostic criteria for LMS, one of whom had affected relatives diagnosed 
clinically with BBS. Both had molecular genetic results diagnostic of BBS, 
implying that the underlying molecular basis for BBS and LMS is the same. 
Moreover, in this study 86% of the patients had a wide-based, unsteady gait, and 
21 c;(. had spasticity. Furthermore, polydactyly does not always occur in patients 
diagnosed as having BBS, as it was absent in 27% of this cohort. There are good 
reasons therefore, to consider BBS and LMS part of the same syndrome and an 
appropriate name would be Laurence-Moon Bardet-Biedl Syndrome (LMBBS). 
VJ j_ 
-t.1 High PreYalence of BBS in Newfoundland 
The prevalence of 1 in 18,000 for BBS in Newfoundland is considerably higher 
than in most other populations. There is a particularly high prevalence of BBS6: 
33?r of the BBS patients in :\ewfoundland have a BBS6 genotype compared 
\Vith --l-7r in other populations (Beales et al, 2001). The molecular data reveal that 
there are at least nine different BBS mutations in the Newfoundland population. 
It is not known if these mutations were brought to Newfoundland by early 
settlers or if the mutations arose in situ. Founder effects, consanguinity, and 
large sibship size are factors that likely increased the prevalence of BBS in 
:'-Jewfouncilancl but one cannot rule out the possibility that there was a 
heterozygous advantage (e.g .. an enhanced ability to store fat) that was selected 
for in the past (Davidson et al. 2003). There is no evidence for assortative 
mating (for example. canier relatives meeting at a clinic for BBS patients) as a 
cause of compound heterozygous mutations at the BBS6 locus in two families. 
The presence of multiple BBS genes and multiple mutant alleles at the BBS6 
locus has been referred to as the 'Newfoundland Paradox' (Katsanis et al, 2001). 
A hypothesis that has been put forward to explain this conundrum suggests that 
BBS is inherited in a multigenic manner rather than as a simple Mendelian 
autUSllm~tl rcccsSJ\'e disorder and that the Newfoundland population is enriched 
for a dominant susceptibility founder locus. The combination of the dominant 
susccptihilit: Iucus '' ith mutations at various BBS loci would produce a higher 
prevalence of BBS than in regions where the frequencies of dominant 
susceptibility loci are low. This proposal has gained support from results 
obtained by screening families for mutations in the known BBS genes. In some 
families a triallelic pattern of transmission has been observed; that is, two allelic 
mutations in one BBS gene and a third mutation in another BBS gene are 
required ror the disease phenotype to be manifest (Badano et al, 2003; Beales et 
al. 2003: Katsanis et al, 2001; Katsanis et al, 2002;). 
Screening for all the known Newfoundland BBS mutations in BBSl, BBS2, and 
BBS6 in the 21 ramilies from whom DNA is available revealed one case of 
possible triallelism. In this family, the affected person is homozygous for a stop 
mutation in BBS2 (Y24X) and is heterozygous for a missense mutation in BBS6 
(A2-J.:2SI. The A242S change was not found in 90 ethnically matched control 
chromosomes and has been associated previously with McKusick-Kaufman 
syndn!me (Stone eta!. 2000) and thus it appears to be a pathogenic mutation 
rather than a polymorphism, though the precise impact of this mutation on the 
family's phenotype is difficult to determine. 
It should also be noted that 31% (46/150) of siblings at risk in the 
:\c'' lllUndl~tild B BS l·amilies are affected. This is considerably higher than the 
12.:'ic; that \\ ould be expected if triallelism were the major mode of inheritance. 
Ho'' C\ er. the possibility that other cases of BBS showing oligogenic inheritance 
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exist in this cohort cannot be excluded without comprehensive mutation 
screening of all known BBS genes. 
4.3 ~atural History 
This is the only reported study of BBS that is population-based, with 
comprehensive ascertainment and extensive follow-up. Protocol-driven 
assessments have allowed standardised data collection over more than 20 years, 
and have enabled accurate calculation of incidence of clinical endpoints. These 
data confirm the severity and early-onset of the visual loss in BBS and the high 
prevalence of obesity which developed to morbid obesity in one quarter of the 
patients. 
The pre\ alence of hypertension and diabetes was higher than previously 
reported (Beales et al, 1999) which may be partly due to the older age of the 
Newfoundland cohort. Howe\·er, both features may develop at a young age (e.g., 
m•o patients had hypertension before they were two years old), so regular 
measurement of blood pressure in BBS patients from birth is recommended. as 
is screening for diabetes from mid-childhood. 
The high pre\alence of structural renal abnormalities in this cohort confirms the 
\aluc of ren~tl ultrasound scan in the diagnostic work-up of BBS. Functional 
renal abnormalities contribute to the morbidity and mortality associated with 
BBS in cl substantial minority, and can occur in infancy. Renal disease was the 
p1imary or contributory cause of death in five of the twelve deaths in this cohort. 
This confirms the findings of a study of Danish BBS patients, which found that 
renal disease was an important factor in half of the fourteen deaths (Riise, 1996). 
Regular monitoring of renal function from early childhood will enable timely 
in ten ention. and help alleviate further morbidity associated with impaired renal 
function. 
4.-l Neurological and Psychiatric Manifestations 
The neurological defects in BBS are widespread and common. There are 
abnormalities involving movements of the face, eyes and limbs, the gait and 
speech. \\ i th preservation of power, suggesting that the defect is central, and is 
primarily one of impaired co-ordination. One may postulate that the disorder 
affects the brainstem with variable involvement of the cerebellar, oculomotor 
and pyramidal tracts. 
The h1gh pre\ alence of neurological and psychiatric abnormalities in this cohort 
implies that the LMBBS genes cause a widespread disturbance in central 
nen ous system development. The paucity of facial muscle movement results in 
a ch,tracteristic expressionless facies, which may give an impression of mental 
ret,trdation. pre\·iously regarded as a cardinal feature of the syndrome (Schachat 
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and Maumenee, 1982). However formal IQ testing shows the majority do not 
have mental retardation. although IQ is in the low normal range (Green et a!, 
1989). 
Beha\ ioural disturbances characteristic of childhood LMBBS include anxiety, 
depression. somatisation, autistic and obsessive traits (Barnett eta!, 2002). In 
this cohort. patients also frequently presented with somatisation, anxiety and 
mood disorders. Psychiatric disease was common, though many patients 
presented repeatedly to physicians, before a psychiatric diagnosis was made and 
appropriate therapy instituted. Psychiatric disease may be underdiagnosed in 
patients with LMBBS. compounded by communication difficulties resulting 
from associated speech defects, learning difficulties. expressionless facies and 
beha\·ioural traits. Early detection and appropriate treatment would improve the 
care of these patients. 
~.5 Phenotype-Genotype Analysis 
This is the !'irst prospective, population-based study to compare the BBS 
phenotype for different genotypes. There is no evidence of a coiTelation between 
genotype and phenotype from these data. Although the phenotype shows 
\·ariahility bct\\een and within genotype groups. the longitudinal data reveal no 
signilic~u1t dil'fercncc in the frequency :mel age to onset of the major clinical 
cndp,llilh ~uch as bl1ndness. diabetes. hypertension. and chronic renal failure. In 
addition. the prevalence of other manifestations such as dystrophy of the 
extremities and obesity show no significant difference with genotype group 
with one exception, polydactyly, which was absent in all five BBS5 patients. 
However. all were members of the same family, and a conclusion cannot be 
reached without further data from other BBSS families. 
These data suggest that the BBS genes are involved at the same point in an early 
developmental pathway, which appears to be critical in the formation of the 
retina, limbs, kidneys, genitalia and central nervous system, and in the 
development of obesity, since abnormalities in all of these systems are common 
in all genotypes. The high prevalence and early onset of hypertension and 
diabetes suggests that the BBS genes may also have a role in the pathogenesis of 
these conditions. Further study is required to evaluate the contribution of the 
BBS genes to non-syndromic obesity, hypertension and diabetes. 
4.6 Craniofacial Dysmorphology 
The findings in this cohort confirm that brachycephaly and macrocephaly are 
characteristic of the disorder (Klein and Ammann, 1969). There is a paucity of 
reports on the facial features of LMBBS. Two independent groups described 
facial features. from photographs of 76 patients (Beales eta!, 1999) and 
ex~1minat1un uf 18 patients (Lorda-Sanchez et al, 2001), which included a long 
philtrum. thin upper lip, small mouth and premature male balding. The results 
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from this study indicate that characteristic findings in LMBBS patients, in 
addition to brachycephaly and macrocephaly, include large ears, short narrow 
palpebral fissures. bitemporal narrowing, a long shallow philtrum, thin upper lip, 
small down turned mouth, and male frontal balding. Increasing awareness of the 
facial dysmorphology may facilitate the early diagnosis of LMBBS. 
4.7 Medical Problems 
Many medical disorders have been described in case reports of LMBBS, but 
there have been few comprehensive studies of the medical problems in large 
groups of LMBBS patients. This study extends the phenotype of LMBBS and 
shows that almost every organ system may be affected, in keeping with the 
wide-spread expression pattern demonstrated for each of the five BBS genes 
identi fiecl thus far (Baclano et al. 2003: Mykytyn et al. 200 l: Mykytyn et al, 
2002: Nishimura et al, 2001; Slavotinek et al, 2000). 
4.7.1 Hepato-biliary Disease 
The underlying obesity may be responsible, at least in part, for some of the 
associated medical problems, such as gastro-esophageal reflux, fatty liver 
causing cle\ atecllivcr enzymes. and gall stone disease. However, the prevalence 
of cholecystectomy found in this coh01t is higher than would be expected for the 
B.'vU of the patients (Stampfer eta!, 1992), suggesting an underlying metabolic 
or structural abnormality predisposing to gall stones. In a survey of 109 LMBBS 
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patients. the prevalence of cholecystectomy for gall stones was only 3% (Beales 
et aL 1999). This lower figure may be partly due to the method of data collection 
by questionnaire. which may have resulted in some under-reporting, and the 
young age of this cohort. 
4. 7.2 Colonic Disorders 
Hirschsprung disease occurs in approximately 1 in 5000 live births (Passarge, 
2002) and has been reported previously in association with LMBBS (Beales et 
al, 1999: Farag and Teebi, 1988; Islek et al, 1996; Lorda-Sanchez et al, 2000; 
Racletti et al, 1988; Slavotinek and Beisecker, 2000), as have other hindgut 
anomalies such as anal stenosis or atresia (Beales et al, 1999; Biedl, 1922; 
Kalangu and Wolf, 1994; Slavotinek and Beisecker, 2000). The presence of one 
case of Hirschsprung Disease and six cases of irritable bowel syndrome in this 
cohort further support the hypothesis that abnormalities of the developing 
hindgut are common in LMBBS. 
4.7.3 Asthma 
The high prevalence of asthma in this cohort confirms the findings of other 
reports (Beales et al. 1997; Beales et al, 1999) in which asthma was present in 
25 of L:V1BBS patients, in association with a BBS1 genotype. In this cohort 
there was no evidence of a relationship between any of the clinical features and 
genotype. and asthma was present in all genotype groups. 
-L7A Congenital Heart Disease 
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The prevalence of 6.5% for congenital heart disease (CHD) in this cohort 
concurs with the results of a survey of 109 LMBBS patients, 7% of whom had 
CHD (Beales et al, 1999). The population-based, comprehensive ascertainment 
of patients m this study means that this figure is likely to be a more accurate 
estimate of the prevalence of CHD in LMBBS than the 32% reported in three 
highly consanguineous Bedouin families, in which other genetic defects may 
ha\·e contributed (Eibeclour et aL 1994). Septal defects and valvular stenosis are 
the most commonly reported, in addition to patent ductus arteriosus and 
cardiomyopathy (Beales eta!, 1999; Blume! and Kniker, 1959; Elbedour eta!, 
1994; Farag eta!, 1999; McLoughlin and Shanklin, 1967; Slavotinek and 
Beisecker, 2000). 
4.7.5 Other Yledical Problems 
The skeletal abnormalities most characteristically associated with LMBBS are 
dystrophic extremities. particularly brachydactyly (Green et al, 1989). In a 
radiographic study of the extremities in 43 LMBBS patients, short, broad bones 
were the most common findings, and a range of other abnormalities were 
present (Rudling et aL 1996). HO\\ever the skeletal dystrophy may be more 
widespread: kyphoscoliosis and talipes equinovarus have been described 
previously in L.\1BBS (Beales et al, 1999; Bell, 1958; Bowen, 1965; Dekaban, 
1972: Farag, 1999; Riise, 1997) and were present in 11% and 4% respectively 
in thi:, cohort. 
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Other medical problems in this cohort which were also reported at increased 
frequency in a survey of 109 LMBBS patients include hypothyroidism and 
chronic serous otitis media (Beales et al, 1999). Both may cause significant 
morbidity and be difficult to detect in a timely manner due to co-morbidity, so 
clinicians managing LMBBS patients should. have a low threshold for initiating 
appropriate investigations. 
5. SCMMARY 
The hypothesis that neurological features and polydactyly can differentiate BBS 
from LMS (Lancet, 1988; Schachat and Maumenee, 1982; OMIM) is 
contradicted by the findings in this cohort of a high prevalence of neurological 
features and the absence of polydactyly in 37% of individuals, most of whom 
exhibit molecular genetic changes of BBS. Furthermore, the finding of patients 
with a clinical diagnosis of LMS and molecular changes diagnostic of BBS 
imply that these are the same disorder, Laurence-Moon-Bardet-Biedl Syndrome 
(LMBBS). 
This study extends the phenotype of LMBBS. This widespread dystrophic 
disorder affects almost every organ system. In addition to retinal dystrophy, 
dystrophic extremities, obesity, genital abnormalities and renal anomalies, 
characteristic craniofacial dysmorphic features occur, and include 
brachycephaly, macrocephaly, large ears, short narrow palpebral fissures, a long 
shallow philtrum. small downturned mouth and premature male balding. 
Associated with this syndrome is a high prevalence of neuropsychiatric 
abnormalities. and a wide range of medical problems including colonic 
abnormalities. gall stone disease and asthma. These findings are consistent with 
the wide-spread expression of each of the five known BBS genes (Badano et aL 
.2003: \-1ykytyn et al. ..2001: :V1yk.ytyn et aL ..2002: ~ishimura et al, 2001; 
Slavotinek et al, 2000), and emphasise the need for regular, thorough clinical 
appraisal of patients with LMBBS. 
The high prevalence of LMBBS in the Newfoundland population is associated 
with multiple genotypes, multiple mutations in the BBS6 gene, and rare 
occurrence of tliallelism. A comparison of the phenotypes with genotypes 
indicates that the dysmorphic, neuropsychiatric and medical abnormalities do 
not appear to vary according to genotype. This implies that the role and function 
of the underlying genes probably operate within a common, ubiquitous 
developmental pathway, which is important in the morphogenesis of the retina, 
limbs. kidney. genitalia, central nervous system, and the development of obesity, 
hypertension and diabetes. 
TABLE 1 : Genotypes and Mutations in Patients with LMBBS identified 
in the Newfoundland Population 
#Patients 
(#families) 
8 (6) 
1 (1) 
5 (1) 
5 (1) 
15(8) 
homozygous 
Gene/Locus 
BBS1 
BBS2 
BBS3 
BBS5 
BBS6 
Mutation 
8 (6) M390R homozygous 
1 (1) Y24X homozygous, and 
A242S heterozygote for BBS6 
Gene not Identified 
Gene not Identified 
4 (2) D143fsX157 (fs1) 
8 (4) F94fsX103 (fs2) homozygous 
2 (1) Fs 1/fs2 
1 ( 1) Fs2/L277P 
2 (1)* Excluded from BBS 1 to 7 
4 (3)* Molecular Investigations 
inconclusive 
1 6 (5)" :'\lo DNA Available 
Fsl= frame shift 1 
Fs2= frame shift 2 
*All these patients are classified as "unknown'' genotype 
.. jj 
TABLE 2: Major Clinical Manifestations in LMBBS 
Clinical Manifestation 
Blindness 
Hypertension 
Diabetes Mellitus 
Number Affected 
91% (42/46) 
67% (31/46) 
48% (22/46) 
Male Hypogenitalism 92% (12/13) 
Obesity 98% (43/44) 
Renal Structural Abnormalities 100% (32/32) 
Chronic Renal Failure 20% (9/44) 
Polydactyly 63% (29/46) 
Brachydactyly 100% (36/36) 
Syndactyly 95% (35/37) 
Mental Retardation (VIQ<70) 33% (8/24) 
46 
TABLE 3: :VIedian Age (and 95% Confidence Intervals) to Onset of 
Yiajor Clinical Endpoints in LMBBS by Genotype 
#Patients Blindness Hypertension Diabetes Mellitus 
BBS1 8 27.0 27.0 43.0 
(6.5-47.5) (9.0-45.0) (41.4-44.6) 
BBS2 1 9.0 
BBS3 5 12.0 34.0 42.0 
(9.9-14.0) (29.7-38.3) (29.1-54.9) 
BBS5 5 21.0 33.0 41.0 
(18.9-23.1) (15.8-50.2) 
BBS6 15 17.0 33.0 36.0 
(13.7-20.3) (29.7-36.3) (27 .8-44.2) 
Unknown Locus 12 18.0 37.0 54.0 
(14.7-21.3) (32.8-41.2) (32.6-75.4) 
Total 46 18.0 34.0 43.0 
( 16.8-19.2) (30.7-37.3) (38.1-47.9) 
TABLE 4: Genital Abnormalities in LMBBS by Genotype 
Abnormality Prevalence Genotypes 
Male 
Small penile length (<10th centile) 92% (12/13) BBS 1, 2, 3, 5, 6, 
Unknown 
Undescended testes 11% (3/26) BBS 6, Unknown 
Hypospadias 8% (2/26) BBS 6, Unknown 
Phimosis 8% (2/26) BBS 1, 6 
Recunent urethral strictures 8% (2/26) BBS 5, 6 
Posterior urethral valves 4% (1/26) BBS 6 
Female 
Vaginal Atresia 10% (2/20) BBS6, Unknown 
Hypoplastic Labia Minora 25% (3112) BBS6, Unknown 
Absent Urethral Opening 5% (1/20) Unknown 
-+8 
TABLE 5: Cranio-facial Dysmorphic Features in the Newfoundland 
LMBBS Patients 
Feature Prevalence 
Brachycephaly 92% (24/26) 
Macrocephaly 58% (15/26) 
Bitemporal Nan·owing 65% (17/26) 
Ear length > 2SD above the mean 61% (16/26) 
Short Palpebral Fissures 77% (20/26) 
Nanow Palpebral Fissures 81% (21/26) 
Ptosis 27% (7/26) 
Shallow Philtrum 35% (9/26) 
Long Philtrum 35% (9/26) 
Thin Upper Lip 54% (14/26) 
Small Mouth 38% (10/26) 
Downtumed Mouth 58% (15/26) 
High Arched Palate 86% (19/22) 
Frontal Balding in Adult Males 92% (11112) 
-l-9 
TABLE 6: :VIedical Problems in the Newfoundland LMBBS Patients 
Medical Problem 
Gastro-intestinal 
Cholecystectomy for gall stones 
Ele\ atedl1 \ er enzvmes 
Gastro-Esophageal Reflux 
Colonic Dysmotility 
Celiac Disease 
Peptic Ulcer Disease 
Skeletal I Connective Tissue 
Kyphoscoliosis 
Talipes Equino\ arus 
Skin 
Pigmented nevi 
Eczema 
Psoriasis 
i\' eu rological 
Epilepsy 
Miscellaneous 
Asthma 
Hyperhidrosis (hands and feet) 
Chronic Serous Otitis Media 
Idiopathic Edema 
Tlwroid Disease 
Myocardial Infarction 
Congenital Heart Disease 
Prevalence Genotypes 
50 
17/46(37%) 
8/33 (24%) 
8/46 (17%) 
7/46 (15%) 
2/46 (4%) 
3/46 (6.5%) 
BBS 1, 3, 5, 6, unknown 
BBS 1, 2, 3, 6 
BBS 1, 5, 6, unknown 
BBS 1, 6, unknown 
BBS 1, unknown 
BBS 5, unknown 
5/46 (11 %) BBS 6, unknown 
2/46 (4%) BBS 3, 6 
6/25 (24%) BBS 1, 5, 6, unknown 
5/46 (11 %) BBS 1, 3, 5, 6, unknown 
3/46 (6.5%) BBS 3, 6 
5/46 (11 %) BBS 6, unknown 
13/46 (28%) BBS 1, 2, 5, 6, unknown 
10/46 (22%) BBS 1, 2, 5, 6, unknown 
9/46 (20%) BBS 2, 3, 6, unknown 
8/46 (17%) BBS 1, 3, unknown 
6/46 (13%) BBS 1, 3, unknown 
6/46 (13%) BBS 1, 3, 6, unknown 
3/46 (6.5%) BBS 6, unknown 
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